Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 11/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17681864 | 0.88 | DRD1 (0.72) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL17682369 | 0.86 | DRD1 (0.60) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL20862239 | 0.86 | DRD1 (0.60) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL17671048 | 0.86 | DRD1 (0.60) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL17682370 | 0.86 | DRD1 (0.60) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL17682384 | 0.86 | DRD1 (0.60) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL17682378 | 0.86 | DRD1 (0.60) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL17670991 | 0.86 | DRD1 (0.60) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL17671011 | 0.85 | DRD1 (0.59) | DRD1CYP3A4HTR1AHTR2BCACNA1B | |
| SCHEMBL17671046 | 0.85 | DRD1 (0.59) | DRD1CYP3A4HTR1AHTR2BCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204374-B1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-04-03 | — | — | EP | claimed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | claimed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | claimed |
| EP-3204374-A1 | ISOINDOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-16 | — | — | EP | claimed |
| WO-2016055482-A1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | claimed |
| EP-3204374-B1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-04-03 | — | — | EP | disclosed |
| EP-3204374-B1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-04-03 | — | — | EP | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| EP-3204374-A1 | ISOINDOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055482-A1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055482-A1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313677-A1 | Isoindoline Derivatives | OPRD1, ADRA1D, DRD2 | DRD1 6/4885CYP3A4 693/4885HTR1A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.